Key Developments For Meridian Bioscience, Inc.
Meridian Bioscience, Inc. (VIVO.O) (Nasdaq)
Meridian Bioscience, Inc. Reaffirms FY 2009 Guidance; Increases Regular Cash Dividend Rate
Meridian Bioscience, Inc. reaffirmed its fiscal 2010 guidance and expects sales to be in the range of $160 to $165 million and per share diluted earnings (EPS) to be between $0.90 and $0.95. Meridian Bioscience, Inc. also announced that it has declared the regular quarterly cash dividend of $0.17 per share for the fourth quarter ended September 30, 2009. The dividend is of record November 23, 2009 and payable December 3, 2009. The Board of Directors has approved an increase to the indicated regular quarterly cash dividend rate of $0.02 bringing the quarterly rate to $0.19 per share for fiscal 2010. This annual indicated dividend rate of $0.76 per share represents a 12% increase over the fiscal 2009 rate of $0.68 per share.
Meridian Bioscience, Inc. Subsidiary Announces Agreement to Distribute Test For GI Disease
Meridian Bioscience, Inc. announced that Meridian Bioscience Europe srl, Milan, Italy has signed an agreement with BÜHLMANN Laboratories AG, Schönenbuch, Switzerland for distribution in Italy of an test for inflammatory conditions of the intestine, Quantum Blue Calprotectin.
Meridian Bioscience, Inc. Granted Special 510(k) Clearance To Add 2009 H1N1 Influenza To TRU FLU Test Package Insert
Meridian Bioscience, Inc. announced that it has been granted a Special 510(k) clearance to update the TRU FLU package insert to include analytical sensitivity claims with two strains of 2009 H1N1 virus cultured from positive respiratory specimens. TRU FLU is a rapid test which identifies influenza A and B in human specimens.
Meridian Bioscience, Inc. Issues FY 2010 Guidance; Revenue Guidance Above Analysts' Estimates; Reaffirms FY 2009 Guidance
Meridian Bioscience, Inc. announced that for fiscal 2010, it expects sales to be in the range of $160 to $165 million and per share diluted earnings (EPS) to be between $0.90 and $0.95. Net income is expected to increase between 15% and 20% from fiscal 2009 to fiscal 2010. The Company also reaffirmed its fiscal 2009 guidance of net sales between $140 million and $144 million and per share-diluted earnings between $0.77 and $0.81 for fiscal 2009. According to Reuters Estimates, analysts were expecting the Company to report revenues of $158 million and EPS of $0.92 for fiscal 2010 and EPS of $0.79 for fiscal 2009.
Meridian Bioscience, Inc. Reiterates FY 2009 Outlook; Declares Regular Cash Dividend
Meridian Bioscience, Inc. reiterated its fiscal 2009 outlook and expects net sales between $140-$144 million and diluted earnings per share (EPS) between $0.77-$0.81. According to Reuters Estimates, analysts were expecting the Company to report revenues of $141 million and EPS of $0.78 for the same period. The Company also announced that declared the regular quarterly cash dividend of $0.17 per share for the third quarter ended June 30, 2009. The record date is July 27, 2009 and the dividend is payable August 7, 2009. The annual indicated cash dividend rate for fiscal 2009 is $0.68 per share, an increase of 21% over the fiscal 2008 rate of $0.56 per share.
